TITLE

Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer

AUTHOR(S)
Glück, Stefan; Gorouhi, Fariborz
PUB. DATE
September 2011
SOURCE
American Journal of Health-System Pharmacy;9/15/2011, Vol. 68 Issue 18, p1699
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The clinical and economic benefits of aromatase inhibitor (AI) therapy in early-stage breast cancer are reviewed. Summary. AI therapy has become a standard of care for the treatment of most postmenopausal women with early-stage breast cancer, as it significantly reduces the risk of disease recurrence and death. Using the currently accepted gold standard for clinical efficacy-improvement in disease-free survival rather than overall survival-exemestane, anastrozole, or letrozole as monotherapy or in sequence with tamoxifen has been found to be superior to tamoxifen monotherapy. Emerging data have demonstrated potential overall survival advantages for AIs subsequent to and directly related to distant recurrence. Of the nonsteroidal AIs, letrozole appears to have the efficacy advantage by demonstrating an early effect on distant recurrence and, subsequently, a potentially significant overall survival benefit, though results of a prospective head-to-head trial of anastrozole and letrozole are not yet available. When the economic burden to society is considered, it appears that all AIs are similarly beneficial on the basis of disease recurrence. However, preliminary analyses indicate that the survival benefit appears to be greater with letrozole than with anastrozole. Thus, considering potential survival benefits and cost-effectiveness, letrozole may be preferable to anastrozole in the early adjuvant setting. Conclusion. AI therapy has become a standard of care for the treatment of most postmenopausal women with early-stage breast cancer. Emerging data have demonstrated potential overall survival advantages for AIs subsequent to and directly related to distant recurrence. When the economic burden to society is considered, it appears that all AIs are similarly beneficial on the basis of disease recurrence.
ACCESSION #
65550731

 

Related Articles

  • Letrozole Prevents More Breast Cancer Recurrences Than Tamoxifen. McBride, Deborah // ONS Connect;Jan2012, Vol. 27 Issue 1, p8 

    The article offers information on a study that highlights the role of letrozole monotherapy in providing greater reduction in breast cancer recurrence and mortality than tamoxifen monotherapy.

  • Switching drugs improves breast cancer patient survival rates.  // British Journal of Hospital Medicine (17508460);Jan2012, Vol. 73 Issue 1, p8 

    The article discusses the Intergroup Exemestane Study, which revealed that postmenopausal women who switched from tamoxifen to exemestane after 2-3 years in adjuvant treatment of 5 years had higher survival rates; comments from lead study author Professor Judith Bliss are also included.

  • Endocrine Therapy Initiation From 2001 to 2008 Varies by Age at Breast Cancer Diagnosis and Tumor Size. Aiello Bowles, Erin J.; Buist, Diana S.M.; Chubak, Jessica; Onchee Yu; Johnson, Jeanene; Chestnut, Janet; Boudreau, Denise M. // Journal of Oncology Practice;Mar2012, Vol. 8 Issue 2, p113 

    Purpose: To evaluate tamoxifen and aromatase inhibitor (AI) initiation over time and by patient characteristics among women diagnosed with breast cancer in a community setting. Methods: We conducted a retrospective cohort study of 1,501 women age ≥ 18 years diagnosed with stages I to II...

  • Nurse prescribing in a breast care unit. Day, Shirley // Nurse Prescribing;Apr2013, Vol. 11 Issue 4, p200 

    Breast cancer has been the most common cancer in the UK since 1997, and now accounts for 31% of all new cancer cases in females (Cancer Research UK, 2012). To provide seamless care for the patients seen in the breast clinic at University College London Hospital, the author has become a nurse...

  • Exemestane reduces breast cancer incidence after menopause.  // Contemporary OB/GYN;Aug2011, Vol. 56 Issue 8, p12 

    The article discusses a study which revealed that exemestane reduces the relative incidence of invasive breast cancer in healthy postmenopausal women. Information about the evaluation of the exemestane and the placebo group with the Gail risk score is presented. Also highlighted is the worsening...

  • Patient-Reported Discontinuation of Endocrine Therapy and Related Adverse Effects Among Women With Early-Stage Breast Cancer. Bowles, Erin J. Aiello; Boudreau, Denise M.; Chubak, Jessica; Onchee Yu; Fujii, Monica; Chestnut, Janet; M. Buist, Diana S. // Journal of Oncology Practice;Nov2012, Vol. 8 Issue 6, pe149 

    Background: Approximately 20% to 50% of women diagnosed with hormone receptor-positive breast cancer discontinue endocrine therapy early; most reports come from automated pharmacy data or small self-report evaluations .We conducted a larger self-report evaluation of endocrine therapy...

  • Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. Colleoni, Marco; Munzone, Elisabetta // Drugs;Aug2015, Vol. 75 Issue 12, p1311 

    Endocrine therapy is a key component of adjuvant treatment for premenopausal patients with endocrine-responsive tumors. It is commonly well tolerated, although side effects are a main concern in the selection of treatment options. Tamoxifen is still considered an adequate endocrine therapy in a...

  • Focus on elderly women with breast cancer. Siddall, Rhonda // British Journal of Hospital Medicine (17508460);Dec2010, Vol. 71 Issue 12, p671 

    The article reports on the call of oncologists Professor Robert Coleman and Dr. Matti Aapro for an increased attention on treating breast cancer in elderly women.

  • Extending therapy may be beneficial for breast cancer.  // Clinical Advisor;Jul2016, Vol. 19 Issue 7, p18 

    No abstract available.

  • Potential role of aromatase inhibitors in the treatment of endometriosis. Hashim, Hatem Abu // International Journal of Women's Health;2014, Vol. 6, p671 

    Endometriosis is an estrogen-dependent chronic inflammatory disease affecting 5%-10% of reproductive-age women, with a prevalence of 5%-50% in infertile women and .33% of women with chronic pelvic pain. Third-generation aromatase inhibitors (AIs) are approved adjuvants for the treatment of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics